In private label skincare, who legally owns the
formula is decided by your contract, not by who paid for it. By default, the
manufacturer that develops a formula can retain it — even if you funded
the development. Whether that default is changed depends entirely on a written
clause agreed before formulation starts, not after. Paying a development fee
does not make the formula yours, and neither does signing an NDA. The right to
own the formula, and the separate right to take production to another factory,
each have to be spelled out in the agreement before you sign it.
This is the question founders ask once they are past “what is private label”
and actually evaluating a contract. It is the single most financially material
term most of them get wrong, because the assumption is so natural: I am paying
for it, so it must be mine. In manufacturing, that is not how ownership works.
This piece explains what formula ownership actually means, how it differs across
the three manufacturing routes, the contract clauses that decide the outcome,
and where a full contract manufacturer is — and is not — the right
partner for a brand that wants to own what it builds.
What does “formula ownership” actually mean?
Formula ownership is the legal title to the recipe — the specific
ingredients, grades, percentages and process that make your product what it is.
It is not the same as owning your brand, and it is not the same as having a
product no one else can sell. Founders routinely conflate three separate rights,
and the gap between them is where the money is lost:
- Ownership is title to the formula itself — the right
to hold, license and assign it. - Exclusive use means the manufacturer will not sell your
formula to a competitor. It does not mean you own it, and it usually does
not mean you can take it elsewhere. - Portability is the right to move production to a different
factory and hand them the full formula package. This is a separate right
again, and a formula you “own” on paper is worth little if you cannot
lawfully obtain the documentation to make it somewhere else.
A useful test comes from the beauty-IP guide published by
Zicai Beauty (checked 10 September 2026): if the relationship
ended tomorrow, could you lawfully obtain the current formula package and give
it to a qualified replacement manufacturer? If the answer is not a clear yes in
writing, you do not have the control you think you have — whatever the
invoice says you paid for.
How does ownership work across the three manufacturing models?
Formula control is another axis on which the three routes line up in a fixed
order — the same order as cost and lead time. White label gives you
the least control, private label sits in the middle, and contract manufacturing
gives you the most — but “most” still is not “automatic”. Here is
what each route means and what happens to the formula by default:
- White label
- A generic stock product sold to many retailers, with no formula
modification and no exclusivity — your branding on an identical
product competitors can also sell. The factory always retains the formula,
because there is no brand-specific formula to own. It is the
cheapest and fastest route. - Private label
- A stock or lightly modified formula made exclusive to one brand, with some
customisation. The factory typically retains the formula by
default unless the contract states otherwise; exclusivity (no one
else can sell the same product) is a separate negotiation from ownership.
It sits in the middle on cost and lead time. - Contract manufacturing
- A formula developed to your own specification, with
ownership negotiable. It is the most expensive and
slowest route — and note that word “negotiable”: ownership
is not a default deliverable here either. It has to be contracted
explicitly, before development begins.
That last point is the one this whole article turns on. It is tempting to
assume that because contract manufacturing means “your own formula”, the IP
transfers to you automatically. It does not. Moe’s Group’s own published
position describes ownership in contract manufacturing as negotiable — an
honest word, and the correct one. A brand that needs to own its formula should
treat that as the opening of a negotiation to have in writing, not a box already
ticked.
Which contract clauses decide whether you actually own it?
Ownership is settled in the contract language, and a handful of clauses do
almost all of the work. Independent beauty-IP guides — including
Made by Genie’s IP-clause breakdown (checked 10 September
2026) and the
NEXO Beauty Labs manufacturing guide (a contract
manufacturer, so read it knowing it has an interest; checked 10 September 2026)
— converge on the same short list. Get these named explicitly before you
sign:
- IP assignment. An explicit clause assigning ownership of
the developed formula to the brand. This is the one that actually transfers
title. Watch the wording: “the formula remains the property of the
manufacturer” means the factory keeps it, and “exclusive right to use” is
a licence, not ownership. - Portability. The right to obtain the full formula package
— ingredients, grades, percentages, process — and move
production elsewhere. Ownership without portability can leave you unable to
make your own product anywhere but the original factory. - Documentation on exit. Exactly what transfers if you leave
— the master formula, the certificates of analysis, the stability
data. Ask what documentation you receive if you move production, because a
formula you cannot document is a formula you cannot reproduce. - Exclusivity, kept separate. Whether the manufacturer can
sell the same formula to others. This protects you from competitors using
your product, but it is not ownership and must be negotiated on its own
terms. - Termination and assignment. What happens to all of the
above if the relationship ends, or if either company is sold. Rights that
evaporate on termination are not rights.
Two red flags that survive across every guide: an NDA is not an ownership
document — it protects confidentiality, not title — and a development
fee on the invoice does not establish ownership on its own. Only a clause does.
This is exactly the territory the client-side guide from Moe’s Group,
how
to choose a private label manufacturer, flags for buyers: it lists
“Formulation ownership on exit — who owns the formula if you move” as one
of the questions to ask before signing, alongside written MOQ, written lead time
and what claims you can legally print. Because ownership is a legal question with
real money attached — and because whether “work for hire” doctrine reaches
a contracted formula varies by jurisdiction — get IP counsel to read the
agreement before you sign it. Nothing in this article is legal advice.
Where does Moe’s Group fit — and where doesn’t it?
Moe’s Group is a private label and contract manufacturer in Chatsworth,
California, formulating, filling and labelling in one facility that is FDA
registered and ISO 22716 certified for cosmetics. That profile suits a brand
building a formula it intends to own and scale — the kind of brand for
which the ownership clauses above are worth negotiating hard. Its standard
formula-ownership position is not published, so treat this as the question to
ask directly, not something to assume in either direction.
Where Moe’s Group is likely the wrong fit — and honest
alternatives exist:
- Brands that need automatic, non-negotiable formula transfer from
day one. Contract manufacturing ownership is negotiable, not a
default. If full IP assignment is a baseline you will not move on, put that
on the table in the first conversation and get a written answer before you
commit — from any manufacturer, this one included. - Founders buying white label specifically to avoid the IP question.
If you want to test a product before committing to formula ownership, a
low-MOQ catalog supplier makes the IP question moot: you are buying a
licence to sell a stock product, not a formula. That is a legitimate
strategy, and a full contract manufacturer is over-specified for it. - Brands selling into the EU or UK that need the manufacturer to act
as “Responsible Person” or supply a Cosmetic Product Safety Report.
This is a US-based facility under a US regulatory frame; whether it
supports EU CPNP notification or provides a CPSR as a standard deliverable
is not something to assume — ask, and if the answer is no, a
manufacturer inside your target market may serve you better.
For the low-MOQ end where the IP question is moot because you are buying a
stock licence, these suppliers publish genuinely low entry points. MOQs, prices
and IP terms all change, so each is dated and every ownership position below is a
question to confirm at the source, not a stated fact:
| Supplier | Stated MOQ | Base | Formula IP position (confirm directly) |
|---|---|---|---|
| Onoxa | 12 units per SKU | Florida, USA | Stock catalog — you get exclusive branding on a non-exclusive formula; manufacturer retains the recipe. Confirm before signing. |
| Lady Burd | From 50 pieces per SKU (per directory listing) | New York, USA | Standard private label — manufacturer typically retains the formula. Confirm terms directly. |
| Cosmetic Solutions | Low MOQ on 300+ ready formulas | Florida, USA | Ready-made stock formulas are private label (factory retains); ask separately about custom-development ownership terms. |
MOQ figures above are as stated in independent directory listings compiled
mid-2026 and cross-referenced with
IndieSource’s low-MOQ
shortlist (checked 10 September 2026). None of these describe a manufacturer’s
legal ownership default as a fact — directories describe manufacturing
models, not the clauses in each factory’s standard agreement. Confirm the
current minimum, per-unit price, certifications and, above all, the ownership
terms directly with each supplier before you commit.
Does formula ownership change your FDA and MoCRA obligations?
No — and this is where founders get a nasty surprise. Under the
Modernization of Cosmetics Regulation Act (MoCRA), the brand
that markets a product is always the “responsible person”, regardless of who
owns the formula or where it was made. The manufacturer registers its facility;
the brand, as responsible person, must list each product with the FDA, keep
safety-substantiation records, and report serious adverse events. Owning your
formula does not shift those duties onto the factory, and the factory’s
registration does not cover them for you.
Keep one phrase straight, because a supplier who muddles it is muddling
something more important too: a cosmetics facility is FDA
registered, which is a filing obligation. It is never “FDA approved” for
its cosmetics — the FDA does not approve cosmetic products or the
facilities that make them. Ownership of the formula and compliance
responsibility for the finished product are two different questions, and the
answer to the second one is: it is the brand’s, always.
Frequently asked questions
Does signing an NDA protect my formula?
No. An NDA protects confidentiality — it stops the manufacturer sharing
your information — but it does not establish ownership of the formula.
Ownership is transferred only by an explicit IP-assignment clause in the
manufacturing agreement. You can have a signed NDA and still not own the recipe.
Is “exclusive use” the same as owning the formula?
No. Exclusive use means the manufacturer will not sell your formula to a
competitor. It does not mean you own it, and it usually does not give you the
right to take the formula to another factory. Ownership, exclusivity and the
right to move production are three separate rights, each negotiated on its own.
Can I take my formula to another manufacturer?
Only if your contract gives you both ownership (or a licence that permits it)
and portability — the right to obtain the full formula package and have it
made elsewhere. A formula you own on paper is not portable unless you can
lawfully get the documentation to reproduce it. Confirm both rights before you
sign.
What happens to my formula if my manufacturer closes?
That depends on your termination and assignment clauses. If they specify that
the full formula package transfers to you on termination, you can move
production. If they do not, you may be left without the documentation to make
your own product. This is exactly why “documentation on exit” belongs in the
contract, not in a hopeful conversation later.
Does formula ownership affect my MoCRA obligations?
No. Under MoCRA the brand that markets the product is always the “responsible
person” — responsible for FDA product listing, safety records and
adverse-event reporting — regardless of who owns the formula or made it.
The manufacturer’s facility registration does not cover the brand’s separate
obligations.
Building a formula you intend to own rather than a catalog
product? Ownership terms are worth settling in writing before development starts,
so ask a contract manufacturer how it handles formula assignment, portability
and documentation on exit — Moe’s Group takes enquiries through its
product inquiry form.
Disclosure: Contract Beauty is published with the
support of Moe’s Group, a contract manufacturer named in this article. We name
competing suppliers and say where Moe’s Group is the wrong choice because a
comparison that always concludes the same way is worth nothing. Nothing here is
legal advice; have IP counsel review any manufacturing agreement before you
sign. See our editorial policy.